A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipients

Flavio Vincenti, Robert Mendez, John Curtis, Jimmy Light, Thomas Pearson, You Min Wu, Stephen M. Katz, Enver Akalin, Robert Esterl, Kristene Gugliuzza, Fuad Shihab, Stanley Jordan, Johann Jonsson, Ernesto Molmenti, Ralph Barbeito

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Background. Monitoring cyclosporine microemulsion (CsA-ME; Neoral) exposure 2 hours postdose (C2) has been reported to optimize the efficacy and safety of CsA-ME therapy. The addition of induction therapy to a maintenance regimen including CsA-ME C2 monitoring has not been evaluated. Methods. In all, 123 adult renal transplant recipients were recruited at 14 U.S. centers for this 6-month study. CsA-ME dose was to be titrated to attain C2 targets of 1700 and 1500 ng/ml during posttransplant months 1 and 2, respectively. After 2 months, patients were randomized to one of two groups with different, decreasing C2 targets. Basiliximab, mycophenolate mofetil, and corticosteroids completed the study immunosuppression. Results. Of the 119 evaluable patients, 76% were male, 22% African American, and 66% deceased donor recipients. Biopsy-proven acute rejection occurred in 10 patients (9.3%); there were two failed grafts and one death. Serum creatinine and calculated GFR values suggest good renal function, with month 6 medians of 1.5 ng/ml and 67 ml/min/ 1.73m2. Safety and tolerability assessments revealed no unexpected outcomes. Observed C2 levels were generally lower than protocol targets, particularly in the first weeks posttransplantation. Conclusions. The striking efficacy and outcomes may have been achieved in this study with lower C2 levels of CsA-ME because of the addition of basiliximab induction.

Original languageEnglish (US)
Pages (from-to)910-916
Number of pages7
JournalTransplantation
Volume80
Issue number7
DOIs
StatePublished - Oct 15 2005
Externally publishedYes

Keywords

  • C2
  • Cyclosporine
  • Kidney transplantation
  • Rejection

ASJC Scopus subject areas

  • Transplantation

Fingerprint Dive into the research topics of 'A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipients'. Together they form a unique fingerprint.

  • Cite this

    Vincenti, F., Mendez, R., Curtis, J., Light, J., Pearson, T., Wu, Y. M., Katz, S. M., Akalin, E., Esterl, R., Gugliuzza, K., Shihab, F., Jordan, S., Jonsson, J., Molmenti, E., & Barbeito, R. (2005). A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipients. Transplantation, 80(7), 910-916. https://doi.org/10.1097/01.TP.0000173802.70980.50